Last Price
40.75
Today's Change
+0.49 (1.21%)
Day's Change
40.00 - 41.31
Trading Volume
22,663
Market Cap
1 Billion
Shares Outstanding
26 Million
Avg Volume
9,617
Avg Price (50 Days)
39.25
Avg Price (200 Days)
27.60
PE Ratio
-23.42
EPS
-1.74
Earnings Announcement
11-Nov-2024
Previous Close
40.26
Open
40.00
Day's Range
40.0 - 41.0
Year Range
15.25 - 42.1
Trading Volume
22,663
1 Day Change
1.22%
5 Day Change
1.07%
1 Month Change
2.54%
3 Month Change
3.19%
6 Month Change
76.18%
Ytd Change
63.00%
1 Year Change
152.95%
3 Year Change
32.87%
5 Year Change
107.91%
10 Year Change
107.91%
Max Change
107.91%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.